Abstract
Purpose Synaptotagmin-1 (SYT1) is a critical mediator of neurotransmitter release in the central nervous system. Previously reported missense SYT1 variants in the C2B domain are associated with severe intellectual disability, movement disorders, behavioural disturbance and EEG abnormalities. Here, we expand the genotypes and phenotypes and identify discriminating features of this disorder.
Methods We describe 22 individuals with 15 de novo missense SYT1 variants. Evidence for pathogenicity is discussed, including ACMG criteria, known structure-function relationships, and molecular dynamics simulations. Quantitative behavioural data for 14 cases are compared to other monogenic neurodevelopmental disorders.
Results Four variants lie in the C2A domain with the remainder in the C2B. We classify 6 variants as pathogenic, 4 as likely pathogenic, and 5 as variants of uncertain significance. Prevalent clinical phenotypes include delayed developmental milestones, ophthalmic problems, abnormal EEG, movement disorders and sleep disturbance. Discriminating behavioural characteristics were severity of motor and communication impairment, presence of motor stereotypies and mood instability.
Conclusion SYT1 variants associated with neurodevelopmental disorder extend beyond previously reported regions, and the phenotypic spectrum encompasses a broader range of severity than initially reported. This work guides diagnosis and molecular understanding of this rare neurodevelopmental disorder, and highlights a key role for SYT1 function in emotional regulation, motor control and emergent cognitive function.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
HM is supported by an Australian Government Research Training Program Scholarship. SLG and HM are supported by Grant 2003710 from The National Health and Medical Research Council (NHMRC) of Australia and a Florey Fellowship. The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. This project was supported by funding to KB from the UK Medical Research Council (G101400), the Baily Thomas Charitable Trust, and Great Ormond Street Hospital Childrens Charity. FB and JJZ were supported by the Indiana University Precision Health Initiate.The study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from https://decipher.sanger.ac.uk and via email from decipher{at}sanger.ac.uk. Funding for the DECIPHER project was provided by Wellcome Trust. Individuals who contributed to DECIPHER bear no responsibility for the interpretation of the data by the authors. We acknowledge the DDD study for identification of variants reported in this paper. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003] a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Trust Sanger Institute [grant no. WT098051]. See Nature 2015; 519:223-8 or www.ddduk.org/access.html for full acknowledgement.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted within the Phenotypes in Intellectual Disability project, which received approval from Cambridge Central Research Ethics Committee (REC ref: IRAS 83633). Written informed consent was provided by each diagnosed individuals parent or consultee prior to information sharing by referring clinicians, and questionnaire completion by parents or carers.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Reporting of SYT1 variants in open access repositories is listed in Table S3. Molecular dynamics simulation data not included in the Supplementary Material are available upon request to the corresponding author.
